Futura Medical Plc (FAMDF) 0.4280 $FAMDF Cellulite

New Post Public Reply Private Reply Replies (0) Message Board

Oct 11, 2015 at 9:00 AM

Futura Medical Plc (FAMDF) 0.4280 $FAMDF

Cellulite Global Clinical Trials Review, H1, 2015
M2 - Thu Sep 24, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/65jxhb/cellulite_global) has announced the addition of the "Cellulite Global Clinical Trials Review, H1, 2015" report to their offering. This report provides an overview of Cellulite clinical trials scenario. This report provides top line data relating to the clinical trials on Cellulite. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials are collated from 80 different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Reasons to Buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned - ALIO MEDICA - Endo International - Futura Medical - Halozyme Therapeutics - L. Manetti H. Roberts & C. - Nutrasource Diagnostics - Premier Research - Royal DSM - Venus Remedies For more information visit http://www.researchandmarkets.com/research/65...ite_global

Global Erectile Dysfunction Pipeline Review 2015
M2 - Tue Sep 08, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bhsbsn/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Erectile Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Erectile Dysfunction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acorda Therapeutics, Inc. - Apricus Biosciences, Inc. - Aprogen, Inc. - Bioheart, Inc. - Biolab Sanus Farmaceutica Ltda. - Corridor Pharmaceuticals Inc. - Futura Medical Plc - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Mezzion Pharma Co. Ltd. - Mitsubishi Tanabe Pharma Corporation - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Pacific Therapeutics Ltd. - Palatin Technologies, Inc. - Pharmicell Co., Ltd. - Sagene Pharmaceuticals, Inc. - Suda Ltd - Yungjin Pharm Ind. Co., Ltd. For more information visit http://www.researchandmarkets.com/research/bhsbsn/erectile
PTN: 0.80 (unch), APRI: 1.65 (+0.03), ACOR: 29.89 (-0.22)

New Generation Topical Pain Relief From Futura Medical
PR Newswire Europe - Wed Jul 15, 4:01AM CDT
LONDON, July 15, 2015 /PRNewswire/ --

Erectile Dysfunction Therapeutic Pipeline Review H2 2015 Market Research Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 1:30PM CST
The report "Erectile Dysfunction - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Erectile Dysfunction. Erectile dysfunction is the failure to get or keep an erection firm enough to have sexual intercourse. However, frequent Erectile dysfunction can be a sign of health problems that need treatment. Erectile dysfunction can have severe mental consequences as it can be joined to relationship difficulties and masculine self-image generally. Research indicates that approximately 40% of males suffer from erectile dysfunction. Complete report is available at http://www.rnrmarketresearch.com/erectile-dys...eport.html .
PTN: 0.80 (unch), APRI: 1.65 (+0.03)

Global Premature Ejaculation Market 2014-2018: Key Vendors are Absorption, Furiex, Innovus and Plethora
M2 - Thu Oct 09, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/thdrgd/global_premature) has announced the addition of the "Global Premature Ejaculation Market 2014-2018" report to their offering. Premature ejaculation is a common sexual dysfunction in men, which is characterized by early discharge of semen. Premature ejaculation can be diagnosed through IELT, which is the average time taken by a man to ejaculate during sexual intercourse. There are two types of premature ejaculation: Primary premature ejaculation and secondary premature ejaculation. The analysts forecast the Global Premature Ejaculation market to grow at a CAGR of 10.20 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Premature Ejaculation market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of premature ejaculation that are available in the market. The report also presents the vendor landscape and a corresponding detailed analysis of the top four vendors in the Global Premature Ejaculation market. In addition, the report discusses the major drivers that influence the growth of the market and outlines the challenges faced by the vendors and the market at large. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Product Profiles 05. Market Research Methodology 06. Introduction 07. Disease Overview and Management 08. Market Landscape 09. Market Segmentation by Route of Administration 10. Market Segmentation by Dosage Form 11. Market Segmentation by Mechanism of Action 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Pipeline Portfolio 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Absorption - Furiex - Innovus - Plethora - Bayer - Dong-A ST - Eli Lilly - Emcure - Endo - Futura Medical - GlaxoSmithKline - Medisyn - Menarini - NeuroHealing - Pfizer - Shionogi - Symyoo - Vectura - Vyrix For more information visit http://www.researchandmarkets.com/research/th..._premature
LLY: 86.14 (+2.37), GSK: 40.22 (+0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navigating New Home Builds: Tucson’s Precise Timelines

Building a Home in Tucson: Timing is Everything Ask anyone who's ever dreamed of their own custom-built home—patience isn't just a virtue, it's a necessity. In Tucson, Arizona, where the landscape is as captivating as it is challenging, Home Remodeling Expert Robin Hartman breaks down exactly what homeowners should expect when embarking on a home build. Hartman, through...

Ebix and intentyx Tackle AI Security in Regulated Fields

Ebix Aims to Rein in AI Mischief When you throw AI agents into the mix of regulated businesses like insurers, banks, and healthcare outfits, you get a storm brewing. Now, Ebix and intentyx seem to be donning their capes, aiming to bring clarity with their new SMARE security platform. Fancy name notwithstanding, this isn't about mind games—it's about real, observable...

PSEG Q3 2026: Mixed Earnings Amidst Storms and Stability

Decoding PSEG's Q3 2026 Performance A company's quarterly performance can feel a bit like checking the weather: you are never quite sure what's coming your way. For PSEG's (NYSE: PEG) third quarter of 2026, the skies were full of mixed signals. Just looking at the headline earnings number, $0.76 per share in net income, there's a drop from last year's $1.24. That’s a...

LITEON's Q3 Surge: Record Profits, AI Focus Amplified

LITEON Smashes Q3 Records, Financials Speak Volumes You don't find numbers like these under every rock. LITEON Technology is rolling in it after clinching third quarter revenues of NT$57.4 billion, marking a significant 9% growth compared to the previous quarter and a whopping 28% surge year-over-year. That's the kind of financial football that gets investors holding onto...

Nexus Capital Buys Coldwater Creek, Eyes Growth Surge

A New Chapter in Apparel Investment You know when you're flipping through those catalog pages or hitting up e-commerce sites, just to find that perfect piece of clothing for a special someone—and you stick with a brand not just outta habit, but 'cause they've got a piece of your history? That's Coldwater Creek and Soft Surroundings, two brands that's been keepin' their...

UFC Gym Expands, Opening Murfreesboro Location Soon

UFC GYM Targets the Heart of Murfreesboro They're doing it again—UFC GYM's tossing another gym into the mix, folks! This time, it's Murfreesboro, Tennessee, catching the brand's punchy, high-energy splash. Don't mistake this for just another big-box, bench-press-jamboree. Their doors swing open come November 14, and this ain't some punk move. We're talking a whopping...

Brightstar Showcases at World Lottery Summit 2026

Brightstar Aims for the Jackpot at WLS 2026 Don't kid yourself—this isn't your granddad's corner-store lottery ticket. Brightstar Lottery PLC, trading as NYSE: BRSL, is pushing the envelope at the World Lottery Summit 2026 in Sydney, flaunting a roster of high-tech and savvy solutions to meet changing player expectations. It's a collision of tradition and tech, all...

Apacer Unveils Cutting-Edge Storage at Electronica 2026

Forging New Paths in Storage Tech Technology waits for no one, and Apacer knows it better than most. At electronica 2026, they're not just tossing out buzzwords—they're backing up promises with cold hard innovations. It's like watching a seasoned chess player thinking ten moves ahead in the game that is techno-evolution. This year, they've hitched a ride on the AI,...

Zensar Sees Solid Revenue Growth in Q2FY27

Zensar's Q2 Performance: Growth Amid Shifting Sands Is Zensar Technologies quietly carving a spot for itself in the cutthroat tech marketplace, or are we just seeing a temporary glimmer during a complex market scenario? With a constant currency growth rate of 4.1% in Q2FY27, Zensar sure seems to have gotten something right. But does this mean they’ve got the long-term...

Lakeland Builds Apartments; Screening Rules Cause Snags

What's the Real Trouble in Lakeland? The Lakeland metro area surely ain't short on apartments after a colossal building frenzy. We're talking a solid 40% bump in just the past five years. You'd figure that'd be enough to solve any housing squeeze, right? But here's the kicker: vacancy rates are stuck at 11.8% — way over the national mean of 7.9%. Discounts like two...